Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis
- PMID: 35873302
- PMCID: PMC9301578
- DOI: 10.1093/ofid/ofac300
Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis
Abstract
Background: Adult respiratory syncytial virus (RSV) vaccines are in the late stages of development. A comprehensive synthesis of adult RSV burden is needed to inform public health decision-making.
Methods: We performed a systematic review and meta-analysis of studies describing the incidence of medically attended RSV (MA-RSV) among US adults. We also identified studies reporting nasopharyngeal (NP) or nasal swab reverse transcription polymerase chain reaction (RT-PCR) results with paired serology (4-fold-rise) or sputum (RT-PCR) to calculate RSV detection ratios quantifying improved diagnostic yield after adding a second specimen type (ie, serology or sputum).
Results: We identified 14 studies with 15 unique MA-RSV incidence estimates, all based on NP or nasal swab RT-PCR testing alone. Pooled annual RSV-associated incidence per 100 000 adults ≥65 years of age was 178 (95% CI, 152‒204; n = 8 estimates) hospitalizations (4 prospective studies: 189; 4 model-based studies: 157), 133 (95% CI, 0‒319; n = 2) emergency department (ED) admissions, and 1519 (95% CI, 1109‒1929; n = 3) outpatient visits. Based on 6 studies, RSV detection was ∼1.5 times higher when adding paired serology or sputum. After adjustment for this increased yield, annual RSV-associated rates per 100 000 adults age ≥65 years were 267 hospitalizations (uncertainty interval [UI], 228‒306; prospective: 282; model-based: 236), 200 ED admissions (UI, 0‒478), and 2278 outpatient visits (UI, 1663‒2893). Persons <65 years with chronic medical conditions were 1.2-28 times more likely to be hospitalized for RSV depending on risk condition.
Conclusions: The true burden of RSV has been underestimated and is significant among older adults and individuals with chronic medical conditions. A highly effective adult RSV vaccine would have substantial public health impact.
Keywords: burden; incidence; pooled; summary; underestimated.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures

Similar articles
-
Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.J Infect Dis. 2023 Jul 14;228(2):173-184. doi: 10.1093/infdis/jiad012. J Infect Dis. 2023. PMID: 36661222 Free PMC article.
-
Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT-PCR.Infect Dis Ther. 2023 Jun;12(6):1593-1603. doi: 10.1007/s40121-023-00805-1. Epub 2023 May 6. Infect Dis Ther. 2023. PMID: 37148463 Free PMC article.
-
Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults.Influenza Other Respir Viruses. 2014 May;8(3):347-52. doi: 10.1111/irv.12234. Epub 2014 Feb 7. Influenza Other Respir Viruses. 2014. PMID: 24512531 Free PMC article.
-
Hospitalizations for acute lower respiratory tract infection due to respiratory syncytial virus in Thailand, 2008-2011.J Infect Dis. 2013 Dec 15;208 Suppl 3:S238-45. doi: 10.1093/infdis/jit456. J Infect Dis. 2013. PMID: 24265483
-
Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis.J Infect Dis. 2022 Mar 15;225(6):1100-1111. doi: 10.1093/infdis/jiaa752. J Infect Dis. 2022. PMID: 33346360 Free PMC article.
Cited by
-
Cost-effectiveness of respiratory syncytial virus vaccination strategies for older Canadian adults: A multi-model comparison.Can Commun Dis Rep. 2025 Feb 12;51(2-3):54-67. doi: 10.14745/ccdr.v51i23a01. eCollection 2025 Feb. Can Commun Dis Rep. 2025. PMID: 39991551 Free PMC article.
-
Estimated Incidence Rate of Specific Types of Cardiovascular and Respiratory Hospitalizations Attributable to Respiratory Syncytial Virus Among Adults in Germany Between 2015 and 2019.Influenza Other Respir Viruses. 2025 May;19(5):e70097. doi: 10.1111/irv.70097. Influenza Other Respir Viruses. 2025. PMID: 40289699 Free PMC article.
-
Role of human infection challenge studies (HICs) in drug development for respiratory syncytial virus (RSV): systematic review and meta-analysis.EBioMedicine. 2025 Jul;117:105765. doi: 10.1016/j.ebiom.2025.105765. Epub 2025 May 29. EBioMedicine. 2025. PMID: 40446400 Free PMC article.
-
Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023.JAMA Netw Open. 2024 Nov 4;7(11):e2444756. doi: 10.1001/jamanetworkopen.2024.44756. JAMA Netw Open. 2024. PMID: 39535791 Free PMC article.
-
Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses.Vaccine. 2024 Dec 2;42(26):126493. doi: 10.1016/j.vaccine.2024.126493. Epub 2024 Oct 30. Vaccine. 2024. PMID: 39476473 Free PMC article.
References
-
- Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749–59. - PubMed
-
- Centers for Disease Control and Prevention. Respiratory syncytial virus (RSV) infection trends and surveillance . Available at: https://www.cdc.gov/rsv/research/us-surveillance.html. Accessed 4 November 2021.
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous